Outputs (2)

Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer (2022)
Presentation / Conference Contribution
Bruce, I., Pang, L., Poole, A., & Fraser, J. (2022, November). Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer. Poster presented at Society for Endocrinology BES 2022, Harrogate

Neuroendocrine castrate resistant prostate cancer (NE-CRPC) is a lethal CRPC subtype that arises as prostate cancer cells transdifferentiate to neuroendocrine cells, evading the potent selective pressure of androgen deprivation therapies (ADT). Curre... Read More about Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer.

Investigating the molecular mechanisms driving neuroendocrine differentiation in androgen deprived prostate cancer cells (2016)
Presentation / Conference Contribution
Sutton, J., Hutchison, G., Fraser, J., & Poole, A. (2016, November). Investigating the molecular mechanisms driving neuroendocrine differentiation in androgen deprived prostate cancer cells. Presented at National Cancer Research Institute Conference, Liverpool, UK

Background: Neuroendocrine differentiation is commonplace in prostate tumors treated with androgen deprivation therapy and is associated with castrate-resistant disease progression and poor prognosis. The molecular mechanisms driving neuroendocrine d... Read More about Investigating the molecular mechanisms driving neuroendocrine differentiation in androgen deprived prostate cancer cells.